Key result
An increase in active MMP-9 over 3 months after bare metal coronary stent placement was significantly associated with the development of clinical in-stent restenosis (p = 0.030).
Why the study?
Does the change in active MMP-9 levels predict clinical in-stent restenosis in patients treated with bare metal stents?
Case-Control (n=432)
Does the change in active MMP-9 levels predict clinical in-stent restenosis in patients treated with bare metal stents?
p-value: p=0.030
An increase in active MMP-9 over 3 months post-PCI is independently associated with the development of clinical in-stent restenosis in patients receiving bare metal stents.
No takes yet. Share an insight, caveat, or question.
MMP-9 rise may flag higher restenosis risk after bare metal stents; hypothesis-generating and requires prospective validation before any clinical role.
Tarr et al. (2013) conducted a case-control in In-stent restenosis of bare metal stents (n=432). Increase in active matrix metalloproteinase-9 (MMP-9) vs. Controls without in-stent restenosis was evaluated on Symptomatic angiographically confirmed in-stent restenosis (ISR) (p=0.030). An increase in active MMP-9 over 3 months after bare metal coronary stent placement was significantly associated with the development of clinical in-stent restenosis (p = 0.030).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: